ArticleBiomacromolecules2025
Impairment of Hyaluronan-Related Glycocalyx Inhibits Macropinocytosis in Cancer Cells via p21 Upregulation.
Article in Biomacromolecules, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Macropinocytosis (MP) in cancer cells is an endocytic process for nutrient extraction initiated by membrane ruffling that supports tumor progression. Hyaluronan (HA), a major component of glycocalyx coating the surface of living cells, is reported to influence the membrane morphology. However, whether HA-related glycocalyx (HA-GCX) regulates MP through membrane reconstruction remains unclear. Here, we demonstrated that the HA-GCX thickness was positively correlated with MP activity in cancer cells. Intriguingly, the disruption of HA-GCX could suppress MP by decreasing membrane ruffle formation. Furthermore, the knockdown of cyclin-dependent kinase inhibitor 1 (CDKN1A/p21) and its downstream matrix metalloproteinase (MMP) 1/9, which were identified to be significantly upregulated following HA-GCX removal, could rescue MP. Importantly, the breakdown of HA-GCX could impede cancer cell proliferation through inhibition of MP. Taken together, our study revealed a novel regulatory role of HA-GCX in MP, which might provide a promising therapeutic avenue in cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.